Literature DB >> 16887640

Colonisation of Clostridium in the body is restricted to hypoxic and necrotic areas of tumours.

P Lambin1, J Theys, W Landuyt, P Rijken, A van der Kogel, E van der Schueren, R Hodgkiss, J Fowler, S Nuyts, E de Bruijn, L Van Mellaert, J Anné.   

Abstract

The use of gene therapy is one of the most recent molecular strategies for the treatment of cancer. It is essential, however, to have an efficient transfer system by which the desired gene can be delivered to the correct environment. The experiments described in this report investigate apathogenic Clostridium as a possible vector to transfer a specific gene product into the extracellular microenvironment of the tumour which is hypoxic/necrotic in parts, using WAG/Rij rats with transplantable rhabdomyosarcomas as a model. Our data show that Clostridium, after systemic administration of at least 10(7) spores, specifically colonises the hypoxic/necrotic areas of our tumour model, the most efficient species being C. acetobutylicum (NI-4082) and C. oncolyticum. Although spores were also detected in normal tissues for up to 4 weeks, they did not germinate in these tissues. We conclude that it seems likely that these bacteria can be used as a selective transfer system into the extracellular environment of tumours which have hypoxic regions. This strategy would be more tumour-specific than various other strategies that are currently being investigated in anti-cancer gene therapy.

Entities:  

Year:  1998        PMID: 16887640     DOI: 10.1006/anae.1998.0161

Source DB:  PubMed          Journal:  Anaerobe        ISSN: 1075-9964            Impact factor:   3.331


  21 in total

Review 1.  Tumour-targeting bacteria engineered to fight cancer.

Authors:  Shibin Zhou; Claudia Gravekamp; David Bermudes; Ke Liu
Journal:  Nat Rev Cancer       Date:  2018-12       Impact factor: 60.716

Review 2.  The Clostridium sporulation programs: diversity and preservation of endospore differentiation.

Authors:  Mohab A Al-Hinai; Shawn W Jones; Eleftherios T Papoutsakis
Journal:  Microbiol Mol Biol Rev       Date:  2015-03       Impact factor: 11.056

3.  Stable Escherichia coli-Clostridium acetobutylicum shuttle vector for secretion of murine tumor necrosis factor alpha.

Authors:  J Theys; S Nuyts; W Landuyt; L Van Mellaert; C Dillen; M Böhringer; P Dürre; P Lambin; J Anné
Journal:  Appl Environ Microbiol       Date:  1999-10       Impact factor: 4.792

Review 4.  Potent and tumor specific: arming bacteria with therapeutic proteins.

Authors:  Nele Van Dessel; Charles A Swofford; Neil S Forbes
Journal:  Ther Deliv       Date:  2015-03

Review 5.  Bacterial components as naturally inspired nano-carriers for drug/gene delivery and immunization: Set the bugs to work?

Authors:  Fatemeh Farjadian; Mohsen Moghoofei; Soroush Mirkiani; Amir Ghasemi; Navid Rabiee; Shima Hadifar; Ali Beyzavi; Mahdi Karimi; Michael R Hamblin
Journal:  Biotechnol Adv       Date:  2018-02-28       Impact factor: 14.227

6.  Insertion or deletion of the Cheo box modifies radiation inducibility of Clostridium promoters.

Authors:  S Nuyts; L Van Mellaert; S Barbé; E Lammertyn; J Theys; W Landuyt; E Bosmans; P Lambin; J Anné
Journal:  Appl Environ Microbiol       Date:  2001-10       Impact factor: 4.792

Review 7.  Salmonella-Mediated Cancer Therapy: Roles and Potential.

Authors:  Vu Hong Nguyen; Jung-Joon Min
Journal:  Nucl Med Mol Imaging       Date:  2016-06-01

Review 8.  Microbial-based therapy of cancer: current progress and future prospects.

Authors:  Nuno Bernardes; Raquel Seruca; Ananda M Chakrabarty; Arsenio M Fialho
Journal:  Bioeng Bugs       Date:  2009-12-02

Review 9.  Engineering the perfect (bacterial) cancer therapy.

Authors:  Neil S Forbes
Journal:  Nat Rev Cancer       Date:  2010-10-14       Impact factor: 60.716

Review 10.  Bacterial therapies: completing the cancer treatment toolbox.

Authors:  Adam T St Jean; Miaomin Zhang; Neil S Forbes
Journal:  Curr Opin Biotechnol       Date:  2008-09-18       Impact factor: 9.740

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.